Selexipag Treatment for Pulmonary Arterial Hypertension Associated with Congenital Heart Disease After Defect Correction: Insights from the Randomised Controlled Griphon Study

Abstract

These post-hoc analyses of GRIPHON provide valuable information about a large population of patients with corrected CHD-PAH, and suggest that selexipag may delay disease progression and was well-tolerated in patients with corrected CHD-PAH.